Filter Results:
(525)
Show Results For
- All HBS Web
(525)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(525)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
- 07 Oct 2014
- First Look
First Look: October 7
(MMRC), and brought together a diverse body of academics, researchers, pharmaceutical and biotech companies, physicians, and patients to combine their efforts around the disease. The MMRF had helped facilitate clinical trials for... View Details
Keywords: Sean Silverthorne
- 19 Mar 2006
- Research & Ideas
Unlocking Your Investment Capital
Neither an asset's cost nor its size specifies its riskiness. For example, consider two assets, $1 billion of a single-drug biotech stock and $1 billion of U.S. Treasury bonds: Each has the same cost and size but they have radically... View Details
- Web
Annual Report 2017 - Annual Report 2017
leaders. See press release Pagliuca Harvard Life Lab The newest addition to the Harvard Innovation Lab (i-lab) ecosystem, the Life Lab—made possible by a gift from Judy (MBA 1983) and Steve (MBA 1982) Pagliuca—offers shared space for high-potential life sciences and... View Details
- 21 Apr 2009
- First Look
First Look: April 21, 2009
this case: http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807106 Note on Biotech Business Development Harvard Business School Note 807-032 Describes the business development process in biotechnology... View Details
Keywords: Martha Lagace
- 08 Sep 2010
- First Look
First Look: September 8, 2010
for a cure; the doubts and obstacles he experiences along the way; and the current options Kremer faces, from returning home to spend time with family to founding a new biotech venture. Through this stark, realistic, and inspiring... View Details
Keywords: Sean Silverthorne
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
prescription drugs that in 1992 it spun off its remaining chemical business to its stockholders. In addition, the American Cyanamid purchase included Immunex, one of the very few biotech startups that had surpassed $100 million in... View Details
- 01 Oct 2000
- News
The Entrepreneurial Venture
instance, who are the customers, and how do they make decisions? O'Lear: I have been involved in microeconomic (company specific) upheaval. Prior to starting a company with two others, I worked at two high-tech companies: a privately held cardiac ultrasound imaging... View Details
- Web
Global Activities 2020-2021 - Global Activities 2021
Harvard Medical School through the Harvard Department of Stem Cell and Regenerative Biology—to explore biotech careers in emerging markets, particularly in the Middle East and North Africa region. Her family’s difficulty obtaining health... View Details
- 01 Sep 2014
- News
All For One
don’t know what the answer is. They have to act, not plan their way forward. Hill began to despair of finding an answer to her problem until a chance meeting with Pixar executive Greg Brandeau in the lobby of a biotech firm—Hill was there... View Details
- 12 Jul 2021
- News
Alumni Confront the COVID-19 Crisis
PYMNTS.com. (Readers who know of groups in need of PPE can email Miller at anne@projectn95.org.) NOVEMBER 23 Cambridge-based biotech Moderna, led by CEO Stephane Bancel (MBA 2000, AMP 170), released promising results on the coronavirus... View Details
- 01 Jun 2007
- News
Mission Possible
“Rudy contends that if we can identify the other ten or twelve genes that are players, we can give the biotech industry so many more shots to come up with a therapy,” explains McCance, who, along with his cofounders, is privately... View Details
- 07 Feb 2017
- First Look
First Look at New Research: February 7
case:https://cb.hbsp.harvard.edu/cbmp/product/517027-PDF-ENG Harvard Business School Case 617-022 Alnylam Pharmaceuticals: Building Value from the IP Estate (B) The leader of a pioneering biotech company in the siRNA space weighs his... View Details
Keywords: Sean Silverthorne
- 03 May 2011
- First Look
First Look: May 3
Business Model Gary P. Pisano, Ryan Johnson, and Carin-Isabel KnoopHarvard Business School Case 611-046 In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this... View Details
Keywords: Sean Silverthorne
- 01 Dec 2010
- News
This Is What I Do
thus deserve our support.” The MJFF raises about $50 million a year. There are prominent backers, such as Google’s Sergey Brin and his wife, Anne Wojcicki, but nearly 55,000 other people made contributions last year. To date the MJFF has supported about ninety View Details
- 01 May 2007
- First Look
First Look: May 1, 2007
drug development process; threats from biotech and generics competitors; pharmaceutical manufacturing, selling, and marketing; and pharmaceutical consumption in Europe, the third world, and the U.S. Merck and Pfizer are analyzed in-depth... View Details
Keywords: Sean Silverthorne
- 12 May 2009
- First Look
First Look: May 12, 2009
this situation, donations are likely to decline, investment surplus has declined and biotech partners are challenged to finance joint projects as well as their own operations. Beall is striving to find a cure for cystic fibrosis while... View Details
Keywords: Martha Lagace
- 01 Sep 2009
- News
E Ink’s Wild Ride
that required a massive amount of investment before it could take off,” says Yoffie, who served on E Ink’s board from 1999 to 2004. “The truism is that getting to that point takes longer and costs more money than the most pessimistic forecast. It’s a very similar... View Details
- 04 Jun 2007
- Research & Ideas
Is Health Care Making You Better—or Dead?
technological innovation, which is how the biotechs and some of the medical devices can get through these hurdles. But for a health service innovation, the payment hurdles are so massive it's masochistic. Then if you go into competition... View Details
- 01 Jun 2018
- News
Up by the Roots
establishing a platform for building relationships among the relevant actors—to be a replicable model of ecosystem development that could be applied anywhere, and to any industry. (At the moment, she is attempting to strike gold twice in one place by boosting New... View Details
- Web
Print View - Course Catalog
Organization The main class tool will be case discussions based on a variety of tough tech ventures, including those pursuing frontier clean energy, material science, biotech and aerospace technologies. We will have case protagonists and... View Details